Psoriatic Arthritis - Pipeline Insight, 2024

Psoriatic Arthritis - Pipeline Insight, 2024

DelveInsight’s, “Psoriatic Arthritis - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriatic Arthritis: Understanding

Psoriatic Arthritis: Overview

Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is similar to rheumatoid arthritis (RA) in symptoms and joint swelling (inflammation). Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and is found in about 20% of such patients with psoriasis. It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP antibodies). The clinical manifestations are varied and can change over time, evolving from one articular pattern to another. Pathogenesis of psoriatic arthritis are not fully understood, but it involves a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints, and other organs. Approximately 33 to 50% of psoriatic arthritis patients have at least one first-degree relative who also has psoriasis or psoriatic arthritis. Genes associated with psoriatic arthritis include those in the HLA region, which are involved in antigen presentation and immune recognition, and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, and signaling, and T cell effector function.

There are no laboratory tests that are specific for psoriatic arthritis. Acute phase reactants such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) may be elevated, as in most inflammatory diseases. However, a normal ESR and CRP should not be used to rule out a diagnosis of psoriatic arthritis as these levels are increased in only about 40% of patients. Radiographic changes show some characteristic patterns in psoriatic arthritis, consisting of erosive changes, gross joint destruction, joint space narrowing, and ""pencil-in-cup"" deformity. These findings are driven by bone destruction and pathologic new bone formation, often in the same digit or even the same joint, which is a characteristic feature of psoriatic arthritis; bone destruction with bone production. Axial features, including sacroiliitis and spondylitis, are characterized by the formation of syndesmophytes (ossification of the annulus fibrosis). The features which differentiate psoriatic arthritis from ankylosing spondylitis are the asymmetric and often unilateral presentation of sacroiliitis and syndesmophytes in psoriatic arthritis are often non-marginal, bulky, asymmetric, and discontinuous skipping vertebral levels. Treatment focuses on controlling inflammation in your affected joints to prevent joint pain and disability and controlling skin involvement. One of the most common treatments are prescription medications called disease-modifying antirheumatic drugs (DMARDs). NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) can relieve pain and reduce inflammation for people with mild psoriatic arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) available without a prescription include ibuprofen (Advil, Motrin IB, others) and naproxen sodium (Aleve). Stronger NSAIDs are available by prescription. Side effects can include stomach irritation, heart problems, and liver and kidney damage. Conventional disease-modifying antirheumatic drugs (DMARDs). These drugs can slow the progression of psoriatic arthritis and save joints and other tissues from permanent damage. The most commonly used disease-modifying antirheumatic drug (DMARD) is methotrexate (Trexall, Otrexup, others). Others include leflunomide (Arava) and sulfasalazine (Azulfidine). Side effects can include liver damage, bone marrow suppression, and lung inflammation and scarring (fibrosis). Targeted synthetic DMARDs. Tofacitinib (Xeljanz) might be used if conventional DMARDs and biologic agents haven't been effective. Higher doses of tofacitinib can increase the risk of blood clots in the lungs, serious heart-related events and cancer. Newer oral medication. Apremilast (Otezla) decreases the activity of an enzyme in the body that controls the activity of inflammation within cells. Apremilast is used for people with mild to moderate psoriatic arthritis who do not want or cannot be treated with DMARDs or biologic agents. Potential side effects include diarrhea, nausea and headaches.

""Psoriatic Arthritis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic Arthritis.

Psoriatic Arthritis Emerging Drugs Chapters

This segment of the Psoriatic Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriatic Arthritis Emerging Drugs

• Izokibep: Affibody

Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that extends half-life. Clinical trial data supports the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase III program in axial spondyloarthritis (AxSpA). Currently, the drug is in Phase IIb/III stage of its clinical trial for the treatment of psoriatic arthritis.

• HS-10374: Hansoh BioMedical R&D Company

HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in phase II stage of its clinical trial for the treatment of psoriasis arthritis.

• KT-294: Kymera

Kymera's KT-294, a pioneering oral TYK2 degrader, has demonstrated exceptional potency, ranging from picomolar to nanomolar levels, across various human cell contexts. This innovative approach uniquely targets TYK2, aiming to mimic the loss-of-function biology seen in humans, thereby achieving near-complete inhibition of the Type I IFN, IL-12, and IL-23 pathways while sparing IL-10. Such a mechanism has the potential to address the limitations of traditional small molecule inhibitors, which often suffer from issues like poor selectivity, limited target engagement, and inadequate activity against Type I IFN. Currently in the preclinical stage, KT-294 is being developed for the treatment of inflammatory conditions including inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.

Further product details are provided in the report……..

Psoriatic Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriatic Arthritis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Psoriatic Arthritis
• There are approx. 20+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Phase II/III include, Affibody.
• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriatic Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic Arthritis drugs.

Psoriatic Arthritis Report Insights

• Psoriatic Arthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriatic Arthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriatic Arthritis drugs?
• How many Psoriatic Arthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic Arthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriatic Arthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriatic Arthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Affibody
• Kymera
• selection Therapeutics GmbH
• Jiangsu HengRui Medicine Co., Ltd.
• Nimbus Lakshmi, Inc.
• Hansoh BioMedical R&D Company
• Bio-Thera Solutions
• ACELYRIN Inc.

Key Products

• Izokibep
• KT-294
• si-544
• SHR0302
• NDI-034858
• HS-10374
• BAT2506
• ABY-035